CAN_381

origin: Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
author: Zhou, X., Weeks, S.D., Ameloot, P., Callewaert, N., Strelkov, S.V., Declerck, P.J.
patent: no
publication_number: not known
patent_application_number: not known
CDR1_seq: IFSPNAMG(predict)
CDR1_length: 8
CDR2_seq: ARTNVGST(predict)
CDR2_length: 8
CDR3_seq: WGQDGWLGQYDY(predict)
CDR3_lentgh: 12
protein_seq: QVQLQESGGGLVQAGGSLRLSCAASGSIFSPNAMGWYRQAPGKERELVAARTNVGSTYADSVKGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCNAWGQDGWLGQYDYWGQGTQVTVSSHHHHHH
DNA_seq: not known
PubMed_ID: 27279497
PDB_ID: 5HVF
PDB_deposition_date: 2016-01-05
PDB_released_date: 2016-06-01
resolution: 2.85Å
source_organism: Vicugna pacos
experiment_method: not known
antigen: TAFI(Thrombin-activatable fibrinolysis inhibitor)
antigen_chain: not known
antigen_source: Homo sapiens
antigen_seq: not known
epitope: not known
IEDB_ID: not known
epitope_reference: not known
function: profibrinolytic therapeutics
validationORprediction: Experimentally Validated
bacteria_family: not known
publication: J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.